Patrick Vermersch
#157,510
Most Influential Person Now
French physician
Patrick Vermersch's AcademicInfluence.com Rankings
Patrick Vermerschmedical Degrees
Medical
#3109
World Rank
#3564
Historical Rank
Neurology
#288
World Rank
#370
Historical Rank
Patrick Vermerschphilosophy Degrees
Philosophy
#8950
World Rank
#12437
Historical Rank
Logic
#5956
World Rank
#7422
Historical Rank
Download Badge
Medical Philosophy
Patrick Vermersch's Degrees
- Doctorate Medicine Université Paris Cité
Why Is Patrick Vermersch Influential?
(Suggest an Edit or Addition)Patrick Vermersch's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. (1992) (1449)
- A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging (1993) (896)
- The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease (1999) (804)
- A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. (2010) (708)
- Neurologic Manifestations in Primary Sjögren Syndrome: A Study of 82 Patients (2004) (602)
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
- Neuromyelitis optica and non organ-specific autoimmunity. (2008) (555)
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study (2017) (341)
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial (2014) (298)
- Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. (2001) (283)
- Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (2004) (257)
- Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria (2015) (234)
- Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event (2014) (232)
- Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study (2016) (231)
- Immunosuppressive therapy is more effective than interferon in neuromyelitis optica (2007) (207)
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis (2011) (205)
- Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. (2001) (202)
- Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy (2011) (193)
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study (2018) (193)
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial (2014) (191)
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
- Natural history of multiple sclerosis with childhood onset. (2007) (188)
- Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile (2002) (182)
- Acute fulminant demyelinating disease: a descriptive study of 60 patients. (2007) (152)
- Neuromyelitis optica in France (2010) (151)
- Specific tau variants in the brains of patients with myotonic dystrophy (1996) (146)
- Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? (1991) (146)
- l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients (2013) (144)
- Idiopathic acute transverse myelitis: Application of the recent diagnostic criteria (2005) (139)
- Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis (2003) (133)
- Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. (1993) (133)
- Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease (1996) (132)
- NMO-IgG and Devic's neuromyelitis optica: a French experience (2008) (120)
- Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. (2004) (118)
- Is neuromyelitis optica associated with human leukocyte antigen? (2009) (114)
- Optical coherence tomography in neuromyelitis optica. (2008) (114)
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study (2011) (114)
- Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases (1997) (114)
- Long-term follow-up of neuromyelitis optica with a pediatric onset (2010) (107)
- Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper (2016) (106)
- Unusual MR findings of the brain stem in arterial hypertension. (2000) (106)
- Cognitive functions in neuromyelitis optica. (2008) (105)
- Interferon-β treatment in patients with childhood-onset multiple sclerosis ☆ (2001) (105)
- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study (2012) (101)
- Long-term follow-up of neurosarcoidosis (2001) (100)
- Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis (2008) (97)
- The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis (2001) (96)
- Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis (2004) (88)
- Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. (2018) (88)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- Sensorineural deafness in X-linked Charcot-Marie-Tooth disease with connexin 32 mutation (R142Q) (1999) (87)
- CSF isoelectrofocusing in a large cohort of MS and other neurological diseases (2004) (87)
- New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. (2005) (86)
- Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. (2015) (85)
- Two‐Dimensional Characterization of Paired Helical Filament‐Tau from Alzheimer's Disease: Demonstration of an Additional 74‐kDa Component and Age‐Related Biochemical Modifications (1997) (81)
- Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease (2005) (78)
- Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatment (2002) (77)
- Morphologic imaging in muscular dystrophies and inflammatory myopathies (2010) (75)
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. (2019) (73)
- Prospective study of patients presenting with acute partial transverse myelopathy (2003) (73)
- The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation (2007) (71)
- New antigenic candidates in multiple sclerosis: Identification by serological proteome analysis (2004) (70)
- JC-virus seroconversion in multiple sclerosis patients receiving natalizumab (2014) (70)
- Rituximab in refractory and non‐refractory myasthenia: A retrospective multicenter study (2012) (70)
- Pathological τ proteins in postencephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders (1997) (68)
- Relapsing demyelinating disease affecting both the central and peripheral nervous systems (2008) (65)
- Interferon-beta treatment in patients with childhood-onset multiple sclerosis. (2001) (65)
- Autonomic dysfunction in multiple sclerosis: cervical spinal cord atrophy correlates (2001) (65)
- Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. (2017) (65)
- Multiple sclerosis and depression: influence of interferon b therapy (2003) (62)
- Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients (2004) (58)
- Dementia in Parkinson's disease: Biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins (1993) (58)
- Neuromyelitis optica and pregnancy (2012) (57)
- Altered B lymphocyte homeostasis and functions in systemic sclerosis. (2018) (57)
- A benign form of neuromyelitis optica: does it exist? (2011) (56)
- Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats (2008) (56)
- Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. (1999) (56)
- Evaluation of health‐related quality of life, fatigue and depression in neuromyelitis optica (2011) (55)
- Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life (2015) (54)
- Association of multiple sclerosis with ILT6 deficiency (2005) (53)
- Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. (2007) (53)
- Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene (2004) (53)
- A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis (2015) (52)
- Long-term outcome of acute and subacute myelopathies (2009) (52)
- Distortion of the Self-Reactive IgG Antibody Repertoire in Multiple Sclerosis as a New Diagnostic Tool1 (2004) (51)
- Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. (1995) (50)
- Cancer and multiple sclerosis in the era of disease-modifying treatments (2011) (50)
- Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease (1996) (49)
- Autonomic and respiratory dysfunction in Charcot–Marie–Tooth disease due to Thr124Met mutation in the myelin protein zero gene (2003) (48)
- Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington’s disease (1998) (48)
- Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. (2015) (47)
- IgG reactivity against citrullinated myelin basic protein in multiple sclerosis (2001) (47)
- Unusual ocular motor findings in multiple sclerosis (2006) (46)
- Comparative efficacy of fingolimod vs natalizumab (2016) (46)
- RELAPSING INFLAMMATORY OPTICNEURITIS: IS IT NEUROMYELITIS OPTICA? (2008) (45)
- Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice (2010) (45)
- Optical coherence tomography in clinically isolated syndrome: no evidence of subclinical retinal axonal loss. (2009) (44)
- Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose? (2016) (44)
- A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: Clinical and pathological findings (2008) (44)
- Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study (2018) (43)
- One-and-a-half syndrome in pontine infarcts: MRI correlates (1999) (43)
- MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study (2013) (43)
- Autoimmune hepatitis and multiple sclerosis: a coincidental association? (2005) (43)
- Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects (1992) (43)
- Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy (2000) (41)
- Siponimod and Cognition in Secondary Progressive Multiple Sclerosis (2020) (41)
- Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion (2010) (41)
- Acute aphasia in multiple sclerosis (2004) (41)
- Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging. (2016) (40)
- Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice (2016) (40)
- Clinical effects of natalizumab on multiple sclerosis appear early in treatment course (2013) (39)
- Long-term follow-up of acute partial transverse myelitis. (2012) (39)
- Visual rating of hippocampal atrophy: correlation with volumetry. (1994) (39)
- Combination of IFNβ‐1a (Avonex®) and mycophenolate mofetil (Cellcept®) in multiple sclerosis (2007) (38)
- Evidence for atrophy of the corpus callosum in Alzheimer's disease. (1994) (38)
- Pupillary disturbances in multiple sclerosis: correlation with MRI findings (2001) (38)
- Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study (2018) (37)
- Punctate pattern (2016) (37)
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial (2021) (37)
- Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. (2006) (37)
- The first European family with tibial muscular dystrophy outside the Finnish population (1998) (37)
- Sativex® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data (2011) (36)
- Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial (2017) (36)
- Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy (2012) (35)
- Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study (2016) (35)
- Social participation in patients with multiple sclerosis: correlations between disability and economic burden (2014) (35)
- A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort (2014) (33)
- Autoantibodies against alpha-fodrin in Sjögren's syndrome with neurological manifestations. (2004) (33)
- White matter magnetic resonance imaging hyperintensity in Alzheimer's disease: correlations with corpus callosum atrophy (1996) (33)
- Multiple sclerosis, interferon beta and clinical thyroid dysfunction (2003) (32)
- Survey of diagnostic and treatment practices for multiple sclerosis in Europe (2017) (32)
- Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study (2014) (32)
- Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study (2012) (32)
- Parkinson's disease and basal ganglia calcifications: Prevalence and clinico-radiological correlations (1992) (31)
- Multiple sclerosis and depression: influence of interferon beta therapy. (2003) (31)
- Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. (2019) (31)
- Clinical and mutational spectrum of limb-girdle muscular dystrophy type 2I in 11 French patients (2009) (30)
- Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene. (2011) (30)
- The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study (2017) (29)
- Radiologically isolated syndrome in children (2017) (28)
- [BCcogSEP: a French test battery evaluating cognitive functions in multiple sclerosis]. (2004) (28)
- Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. (2012) (28)
- 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis (2002) (28)
- Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (2015) (28)
- B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset (2011) (28)
- A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo (2017) (28)
- Principles of a new treatment algorithm in multiple sclerosis (2011) (27)
- Pathologic laughing and intractable hiccups can occur early in multiple sclerosis (2006) (27)
- Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis (2019) (27)
- Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs (2007) (27)
- The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas? (2012) (27)
- Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects (1995) (26)
- NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in Europe (2007) (26)
- Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. (2011) (26)
- Brain MRI in late‐onset multiple sclerosis (2005) (26)
- Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyradiculoneuropathy (2003) (26)
- Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis (2006) (26)
- Guillain-Barré syndrome resembling brainstem death in a patient with brain injury (2001) (26)
- One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis (2005) (26)
- Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. (2004) (25)
- Paroxysmal kinesigenic choreoathetosis as a presenting symptom of multiple sclerosis (2000) (25)
- Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome (2019) (24)
- Longitudinal follow-up of vision in a neuromyelitis optica cohort (2013) (24)
- α-Fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome (2003) (24)
- Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis (2012) (24)
- Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis (2017) (23)
- Does Fatigue Complaint Reflect Memory Impairment in Multiple Sclerosis? (2014) (23)
- [Late onset multiple sclerosis]. (2002) (23)
- Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients (2018) (23)
- Creutzfeldt-Jakob disease (1998) (23)
- Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase (2005) (23)
- Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015. (2016) (22)
- Proinflammatory B-cell profile in the early phases of MS predicts an active disease (2017) (22)
- Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome (2019) (22)
- Extensive myelitis associated with anti-NMDA receptor antibodies (2013) (22)
- Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss (2016) (22)
- High-risk syndrome for neuromyelitis optica: a descriptive and comparative study (2011) (21)
- Brain MRI findings in long-standing and disabling multiple sclerosis in 84 patients (2010) (21)
- Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal tau proteins (2004) (20)
- A new case of autosomal dominant myotonia associated with the V1589M missense mutation in the muscle sodium channel gene and its phenotypic classification (2006) (20)
- Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. (2011) (20)
- Asymptomatic optic nerve lesions (2020) (20)
- Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease (2014) (20)
- CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy (2016) (20)
- The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis (2009) (20)
- The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. (2019) (19)
- Imaging spectrum of Bing–Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström’s macroglobulinemia? (2018) (19)
- Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). (2016) (19)
- Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial (2013) (18)
- Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis (2003) (18)
- Mycophenolate mofetil and neurological diseases (2005) (18)
- Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome (2020) (18)
- 4H syndrome: a rare cause of leukodystrophy (2010) (18)
- Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients. (2020) (18)
- [Neurologic emergencies]. (2004) (18)
- Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. (2002) (17)
- [High prevalence of restless legs syndrome in multiple sclerosis]. (2009) (17)
- The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? (2016) (17)
- Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies (2019) (16)
- No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis (2012) (16)
- Expert opinion on the use of cladribine tablets in clinical practice (2020) (16)
- Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study (2021) (16)
- Delay from treatment start to full effect of immunotherapies for multiple sclerosis. (2020) (15)
- Anti-HMGCR Antibody–Related Necrotizing Autoimmune Myopathy Mimicking Muscular Dystrophy (2017) (15)
- [Demonstration of a specific profile of pathological Tau proteins in frontotemporal dementia cases]. (1995) (15)
- Methionine synthase deficiency: A rare cause of adult-onset leukoencephalopathy (2012) (15)
- Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy (2009) (15)
- Atypical form of non-Langerhans histiocytosis with disseminated brain and leptomeningeal lesions (2000) (15)
- MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. (2014) (15)
- [Hearing loss in multiple sclerosis: clinical, electrophysiologic and radiological study]. (2001) (14)
- High‐affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis (2015) (14)
- Hemifacial spasm due to pontine infarction. (1991) (14)
- Man-in-the-barrel syndrome caused by a pontine lesion (2005) (14)
- Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis (2006) (14)
- Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028) (2016) (13)
- Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis (2020) (13)
- Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. (2019) (13)
- MMP9 is decreased in natalizumab-treated MS patients at risk for PML (2017) (13)
- Interferon β1a (Avonex®) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability (2002) (13)
- Lumbar punctures: use and diagnostic efficiency in emergency medical departments (2009) (13)
- Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study) (2017) (13)
- [Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients]. (1998) (13)
- Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care (2019) (13)
- [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. (2012) (13)
- [Clinical manifestations and therapeutic approach in neurosarcoidosis]. (2000) (12)
- An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017. (2020) (12)
- Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals (2013) (12)
- Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica (2021) (12)
- Congenital myopathy with central cores and fingerprint bodies in association with malignant hyperthermia susceptibility (2001) (12)
- Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levels. (2011) (12)
- JCV serology in time: 3 years of follow‐up (2017) (12)
- [Bilateral phrenic nerve paralysis, dysautonomia and restrictive cardiomyopathy in a case of POEMS syndrome]. (2002) (12)
- Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion (2018) (12)
- Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies (2019) (12)
- Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. (1997) (12)
- Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria (2007) (11)
- Accuracy of Postcontrast 3D Turbo Spin-Echo MR Sequence for the Detection of Enhanced Inflammatory Lesions in Patients with Multiple Sclerosis (2014) (11)
- A family with a novel frameshift mutation in the PMP22 gene (c.433_434insC) causing a phenotype of hereditary neuropathy with liability to pressure palsies (2005) (11)
- Mixed connective tissue disease presenting as trigeminal neuropathy (2014) (11)
- Pulse-Triggered DTI Sequence with Reduced FOV and Coronal Acquisition at 3T for the Assessment of the Cervical Spinal Cord in Patients with Myelitis (2013) (11)
- Cardiac repolarization abnormalities in multiple sclerosis: Spinal cord MRI correlates (2000) (11)
- Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study (2021) (11)
- Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (11)
- An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies (2015) (10)
- [Cortical blindness associated with Guillain-Barre syndrome: a complication of dysautonomia?]. (2005) (10)
- Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (2012) (10)
- Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis (2009) (10)
- [The influence of age and illness duration on cognitive impairment in aging patients with relapsing-remitting multiple sclerosis (RR-MS)]. (2014) (10)
- Novel ε subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome (2008) (10)
- Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★. (2019) (10)
- [Severe Guillain-Barré syndrome and pregnancy: two cases with rapid improvement post-partum]. (2006) (10)
- Syndrome de Gougerot-Sjögren et pupille tonique d’Adie (2005) (10)
- Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial (2009) (9)
- [Neurological manifestations in Sjögren syndrome]. (2010) (9)
- Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002) (2017) (9)
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
- A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006) (2019) (9)
- Periorbital ecchymoses are not pathognomonic of the light-chain type of amyloidosis. (2007) (9)
- Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome (2021) (9)
- [Tubular aggregate congenital myopathy associated with neuromuscular block]. (2001) (9)
- Cerebrovascular symptomatic involvement in sarcoidosis. (2010) (8)
- Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study) (2020) (8)
- Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
- Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease (2009) (8)
- CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis (2021) (8)
- Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management (2018) (8)
- Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis (2022) (8)
- Concomitant therapy for multiple sclerosis (2004) (8)
- Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
- Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort (2020) (8)
- [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects]. (2014) (8)
- Bent spine syndrome as the initial symptom of late‐onset Pompe disease (2017) (8)
- Matrix metalloproteinase 9 is decreased in natalizumab‐treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy (2017) (8)
- [Neuropsychiatric systemic lupus erythematosus (1st part). Cases definitions and diagnosis and treatment of central nervous system and psychiatric manifestations of systemic lupus erythematosus]. (2012) (8)
- [Inaugural psychotic events in multiple sclerosis?]. (2010) (8)
- [Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase]. (2006) (8)
- [Myelopathy - Sjogren's syndrome association: analysis of clinical and radiological findings and clinical course]. (2001) (7)
- [Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. (2017) (7)
- Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS) (2009) (7)
- Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004) (2018) (7)
- Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML (2020) (7)
- Advances in the management of MS symptoms: recently proposed clinical management algorithms. (2015) (7)
- The patient’s perspective: How to create awareness for improving access to care and treatment of MS patients? (2016) (7)
- [Sarcoidosis and progressive multifocal leukoencephalopathy]. (2001) (7)
- Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab (2021) (7)
- Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay. (2008) (7)
- Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (7)
- Mycophenolate mofetil and neurological diseases (2005) (7)
- ENIGM: A French Observational Study about Switching from Natalizumab to Fingolimod in Multiple Sclerosis (S41.002) (2013) (7)
- Double‐blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate‐to‐severe relapses of multiple sclerosis (2020) (7)
- Effect of glatiramer acetate (Copaxone) given orally in human patients: Interleukin‐10 production during a phase 1 trial (2000) (7)
- Untreated patients with multiple sclerosis: A study of French expert centers (2021) (7)
- Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial (2021) (6)
- [Tonic pupils in Sjögren's syndrome]. (2005) (6)
- [Strongyloides stercoralis myelitis]. (1995) (6)
- Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the clarity and clarity extension studies (2019) (6)
- Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies (2021) (6)
- [Primary progressive forms of multiple sclerosis: application of the new diagnostic criteria in French]. (2002) (6)
- Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. (2020) (6)
- [Collet-Sicard syndrome disclosing periarteritis nodosa]. (1998) (6)
- Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis (2019) (6)
- Successful treatment with fingolimod of graft-versus-host disease of the central nervous system. (2018) (6)
- [Fulminant multiple sclerosis]. (2000) (6)
- BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS (2020) (6)
- Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study. (2012) (6)
- Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment (2020) (6)
- Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study (S8.005) (2018) (5)
- Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (2021) (5)
- Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119) (2013) (5)
- Molecular analysis of endogenous retrovirus HRES-1: identification of frameshift mutations in region encoding putative 28-kDa autoantigen. (2001) (5)
- [Adenovirus myelitis and Epstein-Barr myelitis: two unusual viral causes with similar presentations]. (2000) (5)
- Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353) (2017) (5)
- [Treatment of progressive multiple sclerosis with cyclophosphamide]. (2002) (5)
- Cranial nerve involvement in infratentorial progressive multifocal leukoencephalopathy (2012) (5)
- Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (5)
- Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice (2021) (5)
- Cortical Mapping of Pathological Tau Proteins in Several Neurodegenerative Disorders (1997) (5)
- Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084) (2016) (5)
- Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data (2021) (5)
- Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data research. (2020) (5)
- Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis (2022) (5)
- [Normal cerebral aging: study of glial reaction]. (1994) (5)
- SEVERE OEDEMA AFTER SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE (1989) (4)
- Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (4)
- The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis (2007) (4)
- [Fulminating cryptococcal meningoencephalitis. An anatomo-clinical case]. (1990) (4)
- Optical Coherence Tomography - A New Monitoring Tool for Multiple Sclerosis? (2010) (4)
- Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal (2016) (4)
- Severe hypoglycorrhachia after subarachnoid hemorrhage. Two cases with spontaneous recovery in adults. (1987) (4)
- [Neurological manifestations in Sjögren syndrome]. (2005) (4)
- Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis (2020) (4)
- Recurrent multiple cranial nerve palsy and anti‐GD1a antibodies (2011) (4)
- Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. (2019) (4)
- [Magnetic resonance imaging of the facial nerve in a case of Melkerson-Rosenthal syndrome]. (1998) (4)
- Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) (P6.349) (2017) (4)
- [Retroperitoneal fibrosis after treatment with bromocriptine]. (1989) (4)
- Alemtuzumab Controlled Clinical and MRI Outcomes and Slowed Brain Volume Loss in RRMS Patients: 8-Year Follow-up of CARE-MS II Patients (TOPAZ study) (2019) (4)
- [Paraplegia episodes revealing tuberculous myelitis]. (2000) (4)
- Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (4)
- [Presentation of Niemann-Pick type C disease with psychiatric disturbance in an adult]. (2005) (4)
- Some clinical aspects of late onset parkinsonism (1992) (4)
- Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year (2017) (4)
- OCT Findings in Neuromyelitis Optica Spectrum Disorders (2016) (4)
- PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (4)
- Safety of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (3)
- Efficacy of Cladribine Tablets in ORACLE Study Patients Who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline (P3.035) (2016) (3)
- Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequence (2017) (3)
- [Pure subacute pandysautonomia: an assessment of treatment with intravenous polyvalent immunoglobulins]. (2004) (3)
- Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study (S49.005) (2016) (3)
- Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (3)
- Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. (2017) (3)
- Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis. (2019) (3)
- Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis (2022) (3)
- Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it? (2017) (3)
- [Chronic polyradiculoneuritis disclosing sarcoidosis]. (2002) (3)
- Significant and Meaningful Improvement in Treatment Satisfaction with Teriflunomide Versus Subcutaneous IFNB-1A in Patients with Relapsing MS Results from Tenere. (2014) (3)
- [Autologous stem cell transplantation for autoimmune diseases: recommendations from the SFGM-TC]. (2014) (3)
- Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. (2020) (3)
- Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
- [Hypertrophy of the biceps surae after post-radiation lumbar radiculopathy]. (2003) (3)
- [Morphological imaging in the diagnosis of dementia. II. Vascular dementia]. (1995) (3)
- Possible revelation of latent myasthenia gravis by labetalol chlorhydrate. (1987) (3)
- Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study (2010) (3)
- Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095) (2016) (3)
- Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (3)
- Successful treatment with fingolimod of graft-versus-host disease of the central nervous system. (2018) (3)
- Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies (2021) (3)
- Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.369) (2018) (3)
- [Ataxic neuropathy associated with disialosylated antibodies: description of new clinical and biochemical forms]. (2004) (3)
- [Phenotypic aspects of FKRP-linked muscular dystrophy type 2I in a series of eleven patients]. (2007) (3)
- The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. (2022) (3)
- [Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus]. (2012) (3)
- [Cavitary lesions in multiple sclerosis: multicenter study on twenty patients]. (2013) (3)
- Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study (P2.114) (2016) (3)
- Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
- [Medical-social aspects of multiple sclerosis]. (2001) (3)
- The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges (2020) (3)
- Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype (2022) (3)
- Changes Related to Age in Natural and Acquired Systemic Self-IgG Responses in Malaria (2011) (2)
- Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study (2022) (2)
- [Polymyositis revealing a Sjogren's syndrome]. (2010) (2)
- Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis (2018) (2)
- Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128) (2020) (2)
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in (2022) (2)
- FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (2)
- [Late onset of type I familial amyloid neuropathy: results of biopsy from accessory salivary glands]. (1999) (2)
- [Spinal cord magnetic resonance imaging in multiple sclerosis: importance of determining degree of atrophy as a marker of disease course]. (2000) (2)
- Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058) (2016) (2)
- [A breakthrough for the treatment of spasticity in multiple sclerosis]. (2015) (2)
- [Long-term selegiline tolerance in the treatment of Parkinson's disease]. (1992) (2)
- General cortical involvement in a late-onset case of Alzheimer disease. A biochemical approach by quantitation of abnormal tau proteins. (1993) (2)
- Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study (2011) (2)
- Lymphocyte Counts in Patients Treated With Teriflunomide: Observations From Phase 3 Clinical Trials and the Real-World Teri-PRO Study (P5.376) (2018) (2)
- [Dropped head syndrome: report of two cases]. (2005) (2)
- Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study (2011) (2)
- 6 Pathological Tau proteins are biochemical markers that differentiate several types of neurofibrillary degeneration (1996) (2)
- [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study]. (2008) (2)
- [The immunology of multiple sclerosis: changing concepts]. (2008) (2)
- Dalfampridine for symptomatic treatment of neuromyelitis optica (P5.263) (2015) (2)
- Autoantibodies Against α -Fodrin in Sjögren’s Syndrome with Neurological Manifestations (2004) (2)
- From the fundamentals of multiple sclerosis to clinical management (2011) (2)
- [Subcortical dementia: is a revision of the concept necessary?]. (1995) (2)
- Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets (2022) (2)
- A Rare and Treatable Cause of Medullar Claudication: Spinal Dural Arteriovenous Fistula (2019) (2)
- [Regressive leukoencephalopathy in chronic brucellosis]. (1997) (2)
- Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma. (2018) (2)
- [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]. (2008) (2)
- Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results) (2020) (2)
- Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome (2002) (2)
- Anti-JCV Antibody Prevalence in a French Cohort of MS Patients under Natalizumab (P02.141) (2012) (1)
- Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II (2015) (1)
- Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions (2018) (1)
- Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study (2011) (1)
- [Myelitis as a differential diagnosis of spinal cord tumors]. (2017) (1)
- Isaacs’ syndrome and Hodgkin lymphoma: a rare association (2017) (1)
- [Randomized study during a year of early combination of L-dopa/lisuride in Parkinson disease]. (1991) (1)
- Evaluation of Comprehensive Alemtuzumab Infusion Guidance in Patients With Relapsing-Remitting Multiple Sclerosis: EMERALD Study Design (P7.283) (2015) (1)
- Characteristics of walking fatigability in multiple sclerosis (2014) (1)
- Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms (2017) (1)
- [Non-conventional medicine and multiple sclerosis]. (2008) (1)
- [Subcortical dementia of the Neumann type. Contribution of diagnostic imaging]. (1994) (1)
- Multiple sclerosis with normalneuro‐ophthalmological work‐up:results of focal stimulations inducedby a scanning laser ophthalmoscope (2000) (1)
- 039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets (2018) (1)
- Methionine Synthase Deficiency (cblG): A Rare Cause of Adult Onset Leukoencephalopathy with Reversible Neurological Deficit (P01.124) (2012) (1)
- P213 - Concurrence of inflammatory bowel disease and multiple sclerosis in general population: frequency, phenotypes and clinical course (2009) (1)
- Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up) (2016) (1)
- Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study (2010) (1)
- FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (1)
- Baseline characteristics of patients enrolled in CONCERTO - a study of 0.6 and 1.2 mg/day oral laquinimod for relapsing-remitting multiple sclerosis (P7.216) (2015) (1)
- [Epstein-Barr meningoencephaloradiculitis in a immunocompetent woman]. (2002) (1)
- [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment]. (2007) (1)
- [Neuromeningeal tuberculosis: the contribution of genetic amplification to diagnosis]. (2004) (1)
- MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial (2023) (1)
- Multiple sclerosis with normal neuro-ophthalmological work-up: results of focal stimulations induced by a scanning laser ophthalmoscope. (2000) (1)
- Lymphopenia Rates in Clarity/clarity Extension Are Unrelated to Disease Activity at Baseline (2018) (1)
- Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study (2018) (1)
- [Guillain-Barré syndrome with hallucinations and onirism: an underestimated association]. (2004) (1)
- [Bilateral third cranial nerve palsy triggered by an acute relapse of multiple sclerosis]. (2005) (1)
- Could “Leuko-araïosis” Be Secondary to Wallerian Degeneration in Alzheimer’s Disease? (1990) (1)
- Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study) (2017) (1)
- Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (2023) (1)
- Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure (2017) (1)
- Childhood onset multiple sclerosis: the KIDMUS study in European departments of adult neurology (2005) (1)
- Oral Cladribine Delays Time to Conversion to Clinically Definite MS in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study (P07.114) (2013) (1)
- RNFL as a Surrogate Outcome Marker in Patients with Multiple Sclerosis: Design of the OCTiMS study, Baseline Characteristics and OCT Test Reproducibility (P7.224) (2015) (1)
- Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study (2019) (1)
- [Singular, systemic, self-reactive IgG patterns related to age: relationship with cerebral malaria susceptibility in exposed subjects residing in an endemic area in Abidjan, Côte-d'Ivoire]. (2012) (1)
- THUR 174 The magnify-ms study: mavenclad® tablets in active rms (2018) (1)
- Distribution of Tau-PHF in Brodmann Areas Reveals a Heterogeneity of the Degenerating Process in Rostro-Caudal Regions and as a Function of Age (1992) (1)
- Role of the peripheral nervous system for an appropriate postural preparation during gait initiation in patients with a chronic inflammatory demyelinating polyneuropathy: A pilot study. (2021) (1)
- Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis (2010) (1)
- Rapid and sustained efficacy with cladribine tablet treatment in relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (1)
- Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (Preprint) (2021) (1)
- Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study (P6.360) (2017) (1)
- [Adrenoleukomyeloneuropathy in an adult]. (1993) (1)
- [Polymyositis and cranial neuropathy]. (2007) (1)
- Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide (2022) (1)
- Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results) (2019) (1)
- Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study (2011) (1)
- Evaluation of the Treatment Effect of Cladribine Tablets in the Cohort of Patients Who Had Failed Prior Treatment with Injectable Disease-Modifying Drugs: The CLARITY Relapsing-Remitting Multiple Sclerosis Study (2011) (1)
- [Contribution of morphological imaging in the diagnosis of dementia. I--Alzheimer disease]. (1994) (1)
- Introduction: Do we need multi-stakeholder colloquia in MS? (2016) (1)
- Comparing patient and healthcare professional perceptions on multiple sclerosis management and care - where do their priorities differ? Results from a qualitative survey (2018) (1)
- [Subcutaneous apomorphine in major motor oscillations of parkinsonian patients]. (1992) (1)
- Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets (2022) (1)
- 067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies (2018) (1)
- Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies (2021) (1)
- [Sensory disorders in multiple sclerosis (before optic neuropathy)]. (2001) (1)
- [Between the infection and the vaccine, one must choose]. (1998) (1)
- Conclusions: Calls to action for improving the life of MS patients and their families (2016) (1)
- Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy (2018) (1)
- [Heterogeneity of Alzheimer's disease]. (1993) (1)
- Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis (2020) (1)
- Aalborg Universitet Benefit – risk Assessment of Cladribine Using Multi-criteria Decision Analysis ( MCDA ) for Patients With Relapsing-remitting Multiple Sclerosis (0)
- [Multiple sclerosis. Epidemiology, physiopathology, diagnosis, evolution]. (2000) (0)
- Effects of fampridine on walking parameters, upper limb function, fatigue and quality of life in multiple sclerosis (2014) (0)
- Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study (2019) (0)
- [Kjellin syndrome]. (2001) (0)
- [Pragmatic approach to treatments in multiple sclerosis]. (2009) (0)
- Clinical And Paraclinical Parameters Associated With Brain Atrophy In Newly Diagnosed MS Patients. (S13.004) (2014) (0)
- The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary. (2022) (0)
- A One Year Follow-Up Of JCV Serology With Index Values In A French Natalizumab Treated Multiple Sclerosis Cohort (P4.140) (2014) (0)
- Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis (S33.007) (2017) (0)
- Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study (2015) (0)
- Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study (2011) (0)
- Early interventions to prevent lower urinary tract dysfunction after spinal cord injury: a systematic review (2022) (0)
- Diagnosis and treatment of progressive multiple sclerosis: A position paper (2022) (0)
- PO137 Efficacy of cladribine tablets in high disease activity rms (2017) (0)
- Posters II: MS variants - 2 (2009) (0)
- Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis. (2022) (0)
- P.027 Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses (2018) (0)
- Masitinib treatment in patients with progressive multiple sclerosis : Results of an exploratory phase 2 a clinical study (2012) (0)
- Parkinson ' s disease . tremor and levodopa induced dyskinesias in Chronic thalamic stimulation improves (0)
- THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients (2018) (0)
- Wallerian degeneration contribute to " leuko-araiosis " in sub jects free of any vascular disorder ? (0)
- Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis (2020) (0)
- Differentially Regulated Proteins in the Vitreous of Horses with Equine Recurrent Uveitis ( ERU ) and Eye Healthy Controls (2005) (0)
- Non-tumoral lesions of the spinal cord (2008) (0)
- Myogenic abnormalities in intensive care can hide an uncommon diagnosis (2017) (0)
- OCTiMS Study: A 3-Year Longitudinal Assessment of RNFL Thickness Measured by Optical Coherence Tomography in Patients with Relapsing–Remitting Multiple Sclerosis (S24.001) (2018) (0)
- 054 Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension (2018) (0)
- Novel e subunit mutation of the muscle (2009) (0)
- [Interferon beta-1a (Avonex TM): clinical and MRI impacts]. (1999) (0)
- M1140 Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis in General Population: Frequency, Phenotypes and Clinical Course (2009) (0)
- [Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?]. (2004) (0)
- In conclusion, a diagnosis of CIDP and antiganglio- side antibody testing should be considered in patients with recurrent isolated CNP. (2011) (0)
- Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study) (2018) (0)
- Effects Of Prolonged-Released Fampridine On Walking Parameters, Upper Limb Function, Fatigue And Quality Of Life (P7.246) (2014) (0)
- Short communication Unusual ocular motor findings in multiple sclerosis (2006) (0)
- Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370) (2018) (0)
- Phrenic Nerve Paralysis, Vegetative Symptoms and Restrictive Cardiomyopathy in a Case of Poems Syndrome (2003) (0)
- Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study (2019) (0)
- 043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis (2022) (0)
- 024 CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets (2022) (0)
- Sublcinical optic nerve involvement in CIS patients demonstrated by MRI is associated with McDonald MS 2010 criteria (2016) (0)
- Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (2018) (0)
- Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis (2022) (0)
- Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years (2019) (0)
- Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) (2019) (0)
- Oral Cladribine Safety Profile in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study (P01.177) (2013) (0)
- Speci fi c Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged E ffi cacy of Cladribine Tablets A MAGNIFY-MS Substudy (0)
- Spinal cord MRI in multiple sclerosis. Degree of atrophy as a marker of disease activity 23 references. (2008) (0)
- Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351) (2017) (0)
- The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY) (2006) (0)
- [Interferons and neurologic diseases]. (2002) (0)
- Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study (2010) (0)
- Relationship between Fatigue and Memory Performances in Multiple Sclerosis (P04.116) (2013) (0)
- Diagnosis of Adult Onset Leukodystrophy in a Consecutive Study of 156 Patients (S60.006) (2013) (0)
- A New Monitoring Tool for Multiple Sclerosis (2010) (0)
- Myogenic abnormalities in intensive care can hide an uncommon diagnosis (2017) (0)
- [Multiple sclerosis with sensory disturbances and hyperhidrosis of the hand]. (2004) (0)
- Cladribine Tablets 35 mg/kg Is Efficacious in Patients Aged Above and Below 45 Years with Relapsing Multiple Sclerosis in the Clarity Study (2018) (0)
- Mylopathies aigus: analyse comparative du diagnostic tiologique de 65 cas (1999) (0)
- Biochemical quantification of the Alzheimer-type degenerating process in Brodmann areas, using tau-PHF as markers: Evidence for heterogeneity as a function of topography and age (1992) (0)
- Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial (2023) (0)
- Clinical disorders and therapeutic approaches in neurosarcoidosis 55 references. (2008) (0)
- Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006) (2023) (0)
- P34 Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies (2020) (0)
- Improvements Across Functional Systems Are Maintained Regardless of Early VS Late Confirmed Disability Improvement: CARE-MS 6-Year Follow-Up (2020) (0)
- Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms (2016) (0)
- Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary. (2022) (0)
- Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (2022) (0)
- BEST-MS: A Standardized and Prospective Study Comparing the Efficacy of Natalizumab versus Fingolimod in Active Relapsing Multiple Sclerosis. (769) (2020) (0)
- Leys One-anda-half syndrome in pontine infarcts : MRI correlates (1999) (0)
- Alemtuzumab improves disability and quality of life outcomes over 8 years in patients with RRMS (2019) (0)
- 143 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND (2022) (0)
- Multiple sclerosis (WS-038) Chairpersons: Jyun-ichi Kira, Richard Ransohoff (2010) (0)
- Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis (2020) (0)
- WED 184 Cladribine tablets in clarity patients with high disease activity ms (2018) (0)
- Retinal atrophy in CIS patientsis associated with sublclinical optic nerve involvement (2016) (0)
- Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets (2021) (0)
- Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure (2016) (0)
- [Stiff-Man syndrome with late onset]. (1992) (0)
- [Editorial. Spasticity in multiple sclerosis]. (2012) (0)
- Clinical Efficacy Is Sustained in Relapsing Remitting Multiple Sclerosis Following Treatment Switch to Placebo from Cladribine Tablets in Patients with High Disease Activity at Baseline (2018) (0)
- Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension (2019) (0)
- PO136 Durable efficacy of cladribine tablets: clarity+extension (2017) (0)
- 118 Sustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients (2022) (0)
- Recurrent inflammatory optic neuropathy (RION) (2010) (0)
- Hemiballism hemichorea and striatal infarct (1990) (0)
- How Satisfied with Their Treatment Are Patients with MS? Psychometric Evaluation of the Treatment Satisfaction Questionnaire for Medication (TSQM) (P3.236) (2015) (0)
- A localized postoperative cervical syrinx revealed by orthostatic hypotension. (1998) (0)
- Treatment Satisfaction With Teriflunomide in Patients Switching From a Prior Disease-Modifying Therapy: Results From the Phase 3 TENERE and Phase 4 Teri-PRO Clinical Trials (P6.396) (2018) (0)
- Comparing Patient and Healthcare Professional Perceptions on Multiple Sclerosis Management and Care: A Sub-analysis of Disease Progression Perspectives (2018) (0)
- Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment (2016) (0)
- Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension (P6.363) (2018) (0)
- Low signals on t2(star) and swi sequences in patients with ms with progressive multifocal leukoencephalopathy reply (2016) (0)
- Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension (2018) (0)
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. (2022) (0)
- Isaacs’ syndrome and Hodgkin lymphoma: a rare association (2016) (0)
- [Tibial muscular dystrophy. A rare form of distal myopathy]. (1999) (0)
- Retinal Atrophy Measured by Optical Coherence Tomography Predicts Disability Progression in Multiple Sclerosis (S45.007) (2016) (0)
- NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012) (2023) (0)
- The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus (2022) (0)
- Contents Vol. 76, 2016 (2016) (0)
- Mixed connective tissue disease presenting as trigeminal neuropathy (2013) (0)
- Application of the 2010 MacDonald’s Criteria To A Cohort Of Patients With Clinically Isolated Spinal Cord Syndromes (P1.225) (2014) (0)
- Cognition And Grey Matter Atrophy Are Predictive Of Health Related Quality Of Life In Early Treated Patients With Clinically Isolated Syndrome (P4.175) (2014) (0)
- Questions & Answers (2011) (0)
- Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study (2023) (0)
- [Living with multiple sclerosis]. (2016) (0)
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (2018) (0)
- Safety and Efficacy of Teriflunomide in Patients Switching from Subcutaneous Interferon Beta-1a (P7.275) (2015) (0)
- [Spinal cord disorders and systemic diseases]. (2000) (0)
- SURPASS study will evaluate the benefits associated with switching MS therapy (2010) (0)
- REPLY: (2016) (0)
- 044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study) (2018) (0)
- Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database (2021) (0)
- Safety and Efficacy of Teriflunomide in Patients Switching from Subcutaneous Interferon Beta-1a (P3.107) (2016) (0)
- Letter to the editor (2004) (0)
- New and Evolving Treatment Goals in Multiple Sclerosis – the Role of Teriflunomide (2017) (0)
- PO138 High disease activity in relapsing multiple sclerosis (rms) (2017) (0)
- [Hemiballismus. Hemichorea. Striatal infarction]. (1990) (0)
- WED 185 Clarity: mri outcomes in high disease activity relapsing ms (2018) (0)
- Bene fi t-risk Assessment of Cladribine Using Multi-criteria Decision Analysis ( MCDA ) for Patients With Relapsing-remitting Multiple Sclerosis (0)
- Multi-stakeholder Colloquium – Opportunities and Challenges in Multiple Sclerosis Management (2016) (0)
- Editorial: the pitfalls of combination therapy. (2006) (0)
- [Infectious myelopathies: clinical, serological, and prognostic patterns]. (2004) (0)
- [Immunosuppression with monoclonal antibodies in multiple sclerosis]. (2007) (0)
- Fatigue and Other Patient-Reported Outcomes in Patients With RRMS who Switched to Ocrelizumab: 4-Year Data From CASTING-LIBERTO (P6-3.010) (2023) (0)
- A Benign Form of Neuromyelitis Optica (2011) (0)
- Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up (2020) (0)
- Sustained efficacy in relapsing remitting multiple sclerosis following switch to placebo treatment from cladribine tablets in patients with high disease activity at baseline (2018) (0)
- Diagnostic Tool Repertoire in Multiple Sclerosis as a New Distortion of the Self-Reactive IgG Antibody (2003) (0)
- Creating a consensus evaluation and expert opinion reporting platform for brain MRI in Multiple Sclerosis with higher increased risk of Progressive Multifocal Leukoencephalopathy. (2016) (0)
- [Is leuko-araiosis in Alzheimer's disease, in Parkinson's disease and in healthy elderly persons the result of Wallerian degeneration?]. (1989) (0)
- Correlation between Brain MRI and Health Related Quality of Life in Early Treated MS Patients and Clinically Isolated Syndrome (P03.051) (2012) (0)
- [Editorial: multiple sclerosis]. (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Patrick Vermersch?
Patrick Vermersch is affiliated with the following schools:
